Crispr Therapeutics AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham maintained a Buy rating on the stock and has a $81.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum has given his Buy rating due to a combination of factors that highlight Crispr Therapeutics AG’s promising advancements in gene editing technology. The company recently showcased its innovative SyNTase platform, which demonstrated significant preclinical results in increasing serum AAT levels in a mouse model. This achievement is notable as it shows a competitive edge in the base editing landscape, particularly when compared to similar technologies from competitors like Beam Therapeutics.
Despite being approximately 18 months behind Beam in clinical development timelines, Crispr’s ability to achieve higher serum AAT levels could position it favorably in the market. The smaller size of Crispr’s nucleic acid construct is seen as a potential advantage, possibly leading to more efficient editing outcomes. These factors collectively suggest a strong potential for Crispr Therapeutics AG to maintain a competitive stance in the gene editing sector, justifying the Buy rating.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year.